US20080200783A9 - Method and apparatus for control of skin perfusion for indirect glucose measurement - Google Patents
Method and apparatus for control of skin perfusion for indirect glucose measurement Download PDFInfo
- Publication number
- US20080200783A9 US20080200783A9 US10/384,049 US38404903A US2008200783A9 US 20080200783 A9 US20080200783 A9 US 20080200783A9 US 38404903 A US38404903 A US 38404903A US 2008200783 A9 US2008200783 A9 US 2008200783A9
- Authority
- US
- United States
- Prior art keywords
- tissue
- measurement
- glucose
- skin
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008103 glucose Substances 0.000 title claims abstract description 85
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 84
- 238000005259 measurement Methods 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 62
- 230000010412 perfusion Effects 0.000 title claims abstract description 20
- 239000012491 analyte Substances 0.000 claims abstract description 28
- 230000008878 coupling Effects 0.000 claims abstract description 20
- 238000010168 coupling process Methods 0.000 claims abstract description 20
- 238000005859 coupling reaction Methods 0.000 claims abstract description 20
- 230000003287 optical effect Effects 0.000 claims abstract description 17
- 238000010438 heat treatment Methods 0.000 claims abstract description 14
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 9
- 238000012546 transfer Methods 0.000 claims abstract description 8
- 238000001816 cooling Methods 0.000 claims abstract description 7
- 239000000523 sample Substances 0.000 claims description 34
- RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 238000005070 sampling Methods 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims 8
- 230000008081 blood perfusion Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000002596 correlated effect Effects 0.000 abstract description 2
- 239000003792 electrolyte Substances 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 238000000691 measurement method Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 46
- 206010012601 diabetes mellitus Diseases 0.000 description 26
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 230000003595 spectral effect Effects 0.000 description 14
- 238000013459 approach Methods 0.000 description 12
- 238000012544 monitoring process Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000005670 electromagnetic radiation Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 3
- 238000009529 body temperature measurement Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001331 thermoregulatory effect Effects 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000012628 principal component regression Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JRYYVMDEUJQWRO-UHFFFAOYSA-N 2-methylnicotinamide Chemical compound CC1=NC=CC=C1C(N)=O JRYYVMDEUJQWRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000004468 VIS-NIR spectroscopy Methods 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001413 far-infrared spectroscopy Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001566 impedance spectroscopy Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000004476 mid-IR spectroscopy Methods 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010238 partial least squares regression Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000025488 response to cold Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- -1 tungsten halogen Chemical class 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0223—Operational features of calibration, e.g. protocols for calibrating sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1491—Heated applicators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N2021/3595—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using FTIR
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
Definitions
- This invention relates generally to the field of noninvasive glucose measurement. More particularly, the invention relates to control of optical properties of the sampling site to improve reliability of a noninvasive glucose measurement.
- Diabetes is a chronic disease involving the improper production and utilization of insulin, a hormone that facilitates glucose uptake into cells. While a precise cause of diabetes is unknown, both genetic and environmental factors such as obesity and lack of exercise appear to play roles. Persons with diabetes have increased health risk in three broad categories: cardiovascular heart disease, retinopathy, and neuropathy. Potential disease complications include heart disease and stroke, high blood pressure, kidney disease, neuropathy, retinopathy, diabetic ketoacidosis, skin conditions, gum disease, impotence, and fetal complications.
- the incidence of diabetes is both common and on the increase, making the disease a leading cause of death and disability worldwide.
- the World Health Organization (WHO) estimates that diabetes currently afflicts one hundred fifty-four million people worldwide. Fifty-four million people with diabetes live in developed countries. The WHO estimates that the incidence of diabetes will grow to three hundred million by the year 2025. In the United States, 15.7 million people or 5.9% of the population are estimated to have diabetes. Within the United States, the prevalence of adults diagnosed with diabetes increased by six percent in 1999 and rose by thirty-three percent between 1990 and 1998. This corresponds to approximately eight hundred thousand new cases every year in America. The estimated total cost to the United States economy exceeds $90 billion per year. National Institutes of Health, Diabetes Statistics , Publication No. 98-3926, Bethesda Md. (1997).
- a vital element of diabetes management is the self-monitoring of blood glucose levels in the home environment.
- current monitoring techniques discourage regular use due to the inconvenient and painful nature of drawing blood through the skin prior to analysis. See The Diabetes Control and Complication Trial Research Group, supra.
- noninvasive measurement of glucose has been identified as a beneficial development for the management of diabetes.
- Implantable glucose analyzers eventually coupled to an insulin delivery system providing an artificial pancreas are also being pursued.
- a generalized approach to noninvasive glucose measurement utilizes some form of spectroscopy to acquire the signal or spectrum from a measurement site on the subject's body.
- Techniques include but are not limited to: impedance, Raman, and fluorescence; as well as techniques using light, from the ultraviolet through the infrared [ultraviolet (200 to 400 nm), visible (400 to 700 nm), near-IR (700 to 2500 nm or 14,286 to 4000 cm ⁇ 1 ), infrared (2500 to 14,285 nm or 4000-700 cm ⁇ 1 )].
- a specific near infrared range for noninvasive glucose determination in diffuse reflectance mode is about 1100 to 2500 nm or ranges or sets of ranges therein. K.
- noninvasive glucose analyzer any device that reads glucose from the body without penetrating the skin and collecting a biological sample is classified as a noninvasive glucose analyzer.
- noninvasive glucose measurement has conventionally employed a direct measurement approach, in which the net analyte signal due to the absorption of light by glucose in the tissue is used to calculate the glucose concentration.
- a direct measurement approach in which the net analyte signal due to the absorption of light by glucose in the tissue is used to calculate the glucose concentration.
- NIR near-infrared
- This approach involves the illumination of a spot on the body with near-infrared (NIR) electromagnetic radiation, light in the wavelength range 700 to 2500 nm. The light is partially absorbed and scattered, according to its interaction with the constituents of the tissue. The actual tissue volume that is sampled is the portion of irradiated tissue from which light is collected and transported to the spectrometer detection system.
- Generation of a suitable calibration involves development of a mathematical relationship between an in vivo near-infrared spectral measurement and a corresponding reference blood glucose concentration.
- the model generation process includes the collection of a multiplicity of matched spectrum/reference glucose pairs followed by the calculation of a regression model between the multiple independent variables contained in each spectral vector and the associated single dependent reference glucose value.
- Reference blood glucose values are typically obtained directly through the use of measurement tools like the HEMOCUE (YSI, Inc., Yellow Springs Ohio) or any other reliable invasive glucose analyzer.
- Equation 1 defines a proportionality constant between glucose concentration and spectral light absorbed at a single spectral wavelength in the special case where no interfering spectral signatures are present.
- A is the scalar absorbance measurement at a given wavelength of light
- ⁇ is the molar absorptivity associated with the molecule of interest at the same given wavelength
- b is the distance (or pathlength) that the light travels through the sample
- C concentration of the molecule of interest (glucose).
- A ⁇ bC
- Nonparametric methods of calibration such as neural networks and multiple adaptive regression splines (MARS) can also be used to model an expression analogous to equation 2 in the case where Beer's law deviations are present and the relation becomes nonlinear.
- the primary reference device which is used to develop and evaluate noninvasive calibrations for blood glucose, be as accurate as possible to minimize the uncertainty in the model.
- An instrument with a percentage error of five or less is most desirable.
- An instrument having a percentage error of up to ten would be suitable, though the error of the device being calibrated may increase.
- Spectroscopy-based noninvasive glucose analyzers utilize the measured interaction of the tissue sample with electromagnetic radiation (EMR) or another type of energy input that leads to an emission of EMR to acquire the signal or spectrum.
- EMR electromagnetic radiation
- Examples include but are not limited to Nuclear Magnetic Resonance (NMR) spectroscopy, UV, visible near-infrared, mid-infrared, and far-infrared spectroscopy, tissue impedance spectroscopy, Raman spectroscopy, and fluorescence spectroscopy.
- NMR Nuclear Magnetic Resonance
- the near infrared range for noninvasive glucose determination in diffuse reflectance mode is about 1100 to 2500 nm or ranges therein. Hazen (1995), supra.
- noninvasive techniques are distinct from invasive techniques in that the noninvasive sample is analyzed in-situ, as opposed to invasively extracting a biological sample through the skin for analysis.
- the actual tissue volume that is sampled is the portion of irradiated tissue from which light is reflected or transmitted to the spectrometer detection system. All of these techniques share the common characteristic that, as secondary calibration methods, they require a calibration, model or other transformation to convert the measured signal to an estimate of the glucose concentration using reference measurements based on a primary method, such as invasive measurements from samples of venous or capillary blood.
- a number of spectrometer configurations exist for collecting noninvasive spectra from regions of the body.
- a spectrometer has one or more beam paths from a source to a detector.
- a light source may include a blackbody source, a tungsten-halogen source, one or more LED's, or one or more laser diodes.
- a wavelength selection device may be utilized or a series of optical filters may be utilized for wavelength selection.
- Wavelength selection devices include dispersive elements such as prisms, and gratings of various types.
- Nondispersive wavelength selective devices include interferometers, successive illumination of the elements of an LED array, and wavelength selective filters.
- Detectors may be in the form of one or more single element detectors or one or more arrays or bundles of detectors. Detector materials are selected to obtain the desired signal measurement characteristics over the necessary wavelength ranges. Light collection optics such as fiber optics, lenses, and mirrors are commonly utilized in various configurations within a spectrometer to direct light from the source to the detector by way of a sample.
- the interface of the glucose analyzer to the tissue includes a patient interface module for directing light into and collecting light from the tissue measurement site.
- Optical conduits for directing and collecting light may include a light pipe, fiber optics, a focusing lens system, or a light directing mirror system.
- the scanning of the tissue can be done continuously when pulsation effects do not affect the tissue area being tested, or the scanning can be done intermittently between pulses.
- the collected signal (near-infrared radiation in this case) is converted to a voltage and sampled through an analog-to-digital converter for analysis on a microprocessor based system and the result displayed.
- thermoregulatory control of body temperature.
- Blood at approximately 98° F. is pumped to the outer skin layers to provide nutrients, is a means for waste removal, and is a mechanism for thermoregulatory control.
- heat can be dissipated from the core of the body when increased blood flow is combined with the cooling effects of sweat evaporation on the skin surface.
- heat can also be used to warm a cool skin surface, but rapid heat loss associated with touching cold objects is limited by constrictively reducing blood flow to the superficial tissues.
- These thermoregulatory mechanisms typically use constriction or dilation of capillary vessels and the concomitant variation in blood flow to control the potential for heat transfer to and from the body. Capillary diameters can vary tenfold during these processes.
- a tenfold variation in capillary vessel diameter can lead to substantial changes in the composition and optical properties of the tissue.
- Such variation in the measured tissue sample can lead to poor sampling precision over a sequential series of measurements.
- Sample normalization of a varying signal derived from the heterogeneous, layered structure of skin can be of limited effectiveness due to spectral nonlinearities imposed by the compositional variation of the layers and the sequential path of light through the various layers of skin.
- the broadband source light is filtered uniquely in the wavelength domain by each skin layer according to the changing compositions and varying optical densities that result with a perfusion shift in the tissue.
- the result is that the optical sample is destabilized in a nonlinear manner that is difficult or impossible to normalize with a high degree of accuracy. It follows that the modeling of glucose concentration will be most efficacious under the conditions that variations in the optical properties of the sample are minimized excepting where changes in the optical properties are a direct result of glucose variation.
- Factors affecting sample stability may be environmental or natural physiological variation that can arise from variations in sample site location or time dependent physiologies.
- Environmental factors such as temperature, can affect instrumentation, electronics, and physiological components.
- environmental temperature may affect either or both of the alignment of a spectrometer and the temperature of the probing device, which secondarily affects the tissue temperature upon contact.
- noninvasive glucose determination performed via near-IR spectroscopy the result of these changes is a change in the acquired spectra due to the effect of temperature and pressure on tissue optical properties.
- temperature effects the localized perfusion of the tissue.
- the localized perfusion is important for several reasons.
- vasodilatation of the surface capillaries affects the amount of blood present near the skin surface. This change can effect the glucose concentration in the sampled tissue volume.
- K. Jungheim, T. Koschinsky Glucose Monitoring at the Arm , Diabetes Care, 25:956-960 (2002); and K. Jungheim, T.
- vasodilating agents such as nicotinic acid, methyl nicotinamide, minoxidil, nitroglycerin, histamine, capsaicin, or menthol to increase local blood flow. While tissue perfusion can be increased to maximal levels though application of thermal energy, it has the additional undesirable effect of destabilizing optical properties of the tissue sample.
- the invention provides methods and a system for non-invasively measuring key constituents and properties of tissue.
- a target analyte is measured indirectly based on the natural response of tissue to variations in analyte concentration.
- the indirect method of measuring utilizes factors that are effected by or correlated with the concentration of glucose, such as the index of refraction, electrolyte distribution or reduced scattering coefficient of the bulk tissue.
- An indirect measurement means that an ancillary effect due to changes in glucose concentration is being measured.
- perfusion is monitored and stabilized by spectroscopically measuring a control parameter, such as skin temperature, that directly affects perfusion.
- the control parameter is maintained in a range about a set point, thus stabilizing perfusion.
- Skin temperature is controlled using a variety of means, including the use of active heating and cooling elements, passive devices, such as thermal wraps, and through the use of a heated coupling medium having favorable heat transfer properties.
- FIG. 1 provides a flow diagram of a method for regulating a control parameter at a tissue measurement site according to the invention
- FIG. 2 provides a schematic diagram of a subject interface module according to the invention.
- FIG. 3 shows a schematic diagram of an apparatus for noninvasive glucose determination according to the invention.
- a method for indirectly determining a concentration of a target analyte, such as glucose, non-invasively is described in the commonly-assigned U.S. patent application Ser. No. 10/xxx,xxx (SENS0006), the entirety of which is hereby incorporated by reference as if fully set forth herein.
- the method takes advantage of the fact that tissue properties are responsive to and reflect physiological variations in the tissue related to variations in the concentration of analyte.
- An analytical signal is collected at a sampling site on a subject's body.
- Features are extracted from the analytical signals that are indicative of the target analyte on the sampled tissue.
- Analyte concentration is calculated indirectly by applying a calibration model to the features.
- the extracted features are reflective of changes in tissue properties, which themselves are responsive to and reflect physiological variations in the tissue related to variations in the concentration of analyte.
- indirect measurement measures a target analyte by measuring an ancillary effect of the target analyte.
- FIG. 1 shows a flow diagram of a method for noninvasive glucose determination that includes perfusion control at the sample site.
- perfusion is controlled through the provision of a feedback loop that maintains the control parameter within an acceptable range about a set point.
- blood perfusion increases rapidly and is volatile above skin temperatures of 40° C., thus it is desirable to regulate skin temperature at the sampling site to a range between approximately 30 and 40° C.; preferably the skin temperature is controlled between 30 and 35° C.
- the skin is controlled to within one degree of a control set-point in a range of 30 to 35° C.
- the control set point is established by the environmental conditions and the patient physiology at the time of a periodic instrument bias correction.
- only the outermost 100 ⁇ m of skin temperature need be controlled, as below this depth the capillary bed controls the skin temperature.
- the invention specifically provides a method of indirect measurement as described above, the principle of controlling blood perfusion is also readily applied to noninvasive measurement approaches in which analyte concentration is directly determined based on the net analyte signal.
- local perfusion is monitored spectroscopically and controlled through regulation of the control parameter.
- the invented method generally includes steps of:
- One embodiment of the above invention provides a method and apparatus for minimizing the confounding effects in a noninvasive spectral measurement attributable to shifts in skin temperature at the tissue measurement site.
- Near-infrared measurements of skin combined with associated skin temperature reference measurements are used to develop NIR temperature calibrations that require only NIR tissue scans to predict skin surface temperature.
- Methods of developing calibrations for spectral analysis may employ a variety of multivariate analytical techniques that are well known to those skilled in the art.
- NIR skin temperature calibration is made possible by the known shifting of the 1450 or 1900 nm water band with variations in skin temperature.
- the calibration model incorporates the shift information implicitly in the multivariate regression coefficients.
- Temperature measurement and control of human tissue is important in noninvasive NIR measurement because it provides a means of simplifying the complex overlapping spectral effects that inhibit extraction of the analyte signal.
- the extra temperature measurement hardware and the associated cost and complexity are avoided by using NIR temperature measurement.
- Skin temperature at the measurement site is spectroscopically monitored by calculating temperature values through the application of a multivariate calibration model that correlates spectroscopic changes with shifts in skin temperature.
- thermal time constants imposed by conventional temperature sensing devices are eliminated, providing near-instantaneous temperature readings.
- Temperature control may be either active or passive.
- Passive control is achieved through the selective application and removal of an occlusive thermal wrap.
- Active control is provided by a thermistor applied to the skin in the vicinity of the measurement site. Active and passive control may be applied in complementary fashion or they may be used separately.
- the control means is incorporated into the measurement instrument, wherein the calculated skin temperature values provide the feedback in a closed loop that drives the control device.
- the temperature values are supplied to an operator, who then applies active and/or passive control to achieve and maintain a skin temperature within the target range. By monitoring skin temperature spectroscopically and employing methods of passive and/or active control it is possible to reduce the effects of skin temperature variation on the spectral measurement. Active control may be by way of a conductive element, as described above, or it may also be provided by a radiative element.
- perfusion can be controlled in an open-loop fashion by maintaining skin temperature at a specific set-point, as shown in FIG. 2 .
- the control of skin temperature is performed conductively through heating and cooling element 201 included as part of a patient interface module 200 .
- the heating and cooling element may be energy transfer pads.
- skin temperature is controlled through radiative energy transfer from an energy source.
- the system may include means for monitoring the skin temperature at the measurement site either spectroscopically or through a temperature probe (not shown).
- a noninvasive probe 203 is placed against the skin at the sample site 204 .
- a coupling medium 205 is employed between the patient interface 202 and the tissue 204 . The coupling medium serves to facilitate heat transfer between the patient interface 202 and the tissue 204 .
- the coupling medium itself may serve to control skin temperature at the sampling site.
- a heated coupling medium provides the thermal energy to maintain the skin of a sampling site at or near a set point.
- a number of compounds are suitable for use as a coupling medium; for example, silicone oil. Glycerol and mineral oil could also be used, but they are less desirable alternatives, in view of the fact that both materials contain carbon-hydrogen bonds that could interfere with spectroscopic analysis of an analyte such as glucose.
- a particularly preferred embodiment of the coupling medium is the perfluorinated liquid FLUORINERT, either FC-40 or FC-70 (3M COMPANY, ST. PAUL Minn.). While the FLUORINERT functions to reduce surface reflection variations in the noninvasive 20 measurement, its heat transfer properties are well suited for use as a thermal regulator. Because the FLUORINERT comes into contact with skin at the measurement site, heat can be transferred across the skin if the temperature of the FLUORINERT differs from that of the skin.
- Heated FLUORINERT can be used in place of a heated probe with the advantage of reduced power consumption when compared with a temperature controlled metal probe contact surface.
- the advantage is gained by the rapid heating of small amounts of FLUORINERT just prior to the measurement. Periodic rapid heating saves power over continuous heating of the metal heater contact surface thereby reducing power consumption and lengthening battery life.
- the use of heated FLUORINERT also allows for the relocation of the heating electronics away from the probe for increased safety.
- the use of heated FLUORINERT also allows for the heating of the tissue at the measurement site, which is not heated directly by the probe surface heater as it is not in contact with the tissue at the measurement site.
- the heated FLUROINERT is disposed between the patient interface of the probe and the skin surface of the measurement site.
- the coupling fluid may be heated by the source element in embodiments where the source element is in close proximity to the sampling site.
- FIG. 3 provides a schematic diagram of a preferred embodiment of the sensor.
- the sensor includes a radiation source such as a tungsten halogen near-infrared radiation source 301 , a wavelength selection filter 302 passing light in a range of approximately 1150 to 1850 nm; optional illumination fibers 303 for conveying the source photons to an in-vivo skin sample 204 ; an interface 200 to the sample site, for example, a patient's forearm; detection fibers 306 for gathering diffusely reflected and transflected radiation from the skin to a spectrum analyzer 307 that includes, for example a grating (not shown), and a detector array (not shown) to detect the radiation; an AD (analog-to-digital) converter 308 for converting the detected signal to a voltage; and processing means 309 for converting the voltage into a glucose concentration.
- a radiation source such as a tungsten halogen near-infrared radiation source 301 , a wavelength selection filter 302 passing light in
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
- This application claims benefit of U.S. Provisional Patent Application Ser. No. 60/363,345, filed Mar. 8, 2002; and is a Continuation-in-part of U.S. patent application Ser. No. 09/955,531, filed Sep. 17, 2001, which claims benefit of U.S. Provisional Patent Application Ser. No. 60/235,369, filed Sep. 26, 2000.
- 1. Field of the Invention
- This invention relates generally to the field of noninvasive glucose measurement. More particularly, the invention relates to control of optical properties of the sampling site to improve reliability of a noninvasive glucose measurement.
- 2. Background Information
- Diabetes is a chronic disease involving the improper production and utilization of insulin, a hormone that facilitates glucose uptake into cells. While a precise cause of diabetes is unknown, both genetic and environmental factors such as obesity and lack of exercise appear to play roles. Persons with diabetes have increased health risk in three broad categories: cardiovascular heart disease, retinopathy, and neuropathy. Potential disease complications include heart disease and stroke, high blood pressure, kidney disease, neuropathy, retinopathy, diabetic ketoacidosis, skin conditions, gum disease, impotence, and fetal complications.
- Diabetes Prevalence and Trends
- The incidence of diabetes is both common and on the increase, making the disease a leading cause of death and disability worldwide. The World Health Organization (WHO) estimates that diabetes currently afflicts one hundred fifty-four million people worldwide. Fifty-four million people with diabetes live in developed countries. The WHO estimates that the incidence of diabetes will grow to three hundred million by the year 2025. In the United States, 15.7 million people or 5.9% of the population are estimated to have diabetes. Within the United States, the prevalence of adults diagnosed with diabetes increased by six percent in 1999 and rose by thirty-three percent between 1990 and 1998. This corresponds to approximately eight hundred thousand new cases every year in America. The estimated total cost to the United States economy exceeds $90 billion per year. National Institutes of Health, Diabetes Statistics, Publication No. 98-3926, Bethesda Md. (1997).
- Long-term clinical studies show that the onset of diabetes related complications can be significantly reduced through proper control of blood glucose levels. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Eng J of Med, 329:977-86 (1993); and 1 U.K. Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with
type 2 diabetes, Lancet, 352:837-853 (1998); and 1Y. Ohkubo, H. Kishikawa, E. Araki, T. Miyata, S. Isami, S. Motoyoshi, Y. Kojima, N. Furuyoshi, M. Shichizi, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study, Diabetes Res Clin Pract, 28:103-117 (1995). - A vital element of diabetes management is the self-monitoring of blood glucose levels in the home environment. However, current monitoring techniques discourage regular use due to the inconvenient and painful nature of drawing blood through the skin prior to analysis. See The Diabetes Control and Complication Trial Research Group, supra. As a result, noninvasive measurement of glucose has been identified as a beneficial development for the management of diabetes. Implantable glucose analyzers eventually coupled to an insulin delivery system providing an artificial pancreas are also being pursued.
- Glucose Measurement: History, Approaches, and Technologies
- The treatment of diabetes has progressed through several stages. The combined development of insulin therapy and the development of devices for the self-monitoring of blood glucose in the home led to a radical improvement in the lives of individuals afflicted with diabetes. Self-monitoring of blood glucose has progressed through multiple stages from early testing that used urine samples to the current standard of invasive finger stick samples that are more accurate but somewhat painful. The development of alternative site glucose measurement technology has somewhat mitigated the pain aspects, but poses a biohazard. Alternate site blood glucose concentration levels are also known to differ from those taken at the fingertip during periods when glucose concentrations are rapidly changing. The difference is related to circulatory transport of glucose to peripheral tissues: Alternate site tissue sites with lower blood perfusion than the finger will exhibit a delay in the rise and fall of glucose levels when compared with finger blood glucose.
- Current research is focused on the development of noninvasive technologies that will totally eliminate the pain associated with glucose determination and fluid biohazard issues. Another important area of research involves the combination of automated glucose measurement and insulin therapy. Progress has been reported in the research on implantable or full-loop systems that have been proposed to incorporate both glucose measurement and control through automated insulin delivery. In the interim, a device that provides noninvasive, automatic, or (nearly) continuous measurement of glucose levels would clearly be useful to those afflicted with diabetes. Various systems have been developed with this goal in mind. J. Tamada, S. Garg, L. Jovanovic, K. Pitzer, S. Fermi, R Potts, Noninvasive glucose monitoring comprehensive clinical results, JAMA, 282:1839-1844 (1999) describe a minimally-invasive monitoring system reported that provides three readings of interstitial fluid glucose per hour, each delayed by up to fifteen minutes due to the sample acquisition process. The measurement is made through an electrochemical-enzymatic sensor on a sample of interstitial fluid that is drawn through the skin using an iontophoresis technique. Other approaches, such as the continuous monitoring system reported by T. Gross, B. Bode, D. Einhorn, D. Kayne, J. Reed, N. White and J. Mastrototaro, Performance evaluation of the Minimed® continuous glucose monitoring system during patient home use, Diabetes Technology & Therapeutics, Vol. 2, Num. 1, (2000) involve the surgical implantation of a sensor in tissue. Health risks due to sensor implantation or measurement delay remain as obstacles to efficacious use of these devices in directing insulin therapy. To date, a fully noninvasive alternative has not been approved by the FDA.
- Noninvasive Glucose Measurement
- There exist a number of noninvasive approaches for glucose determination. These approaches vary widely, but have at least two common steps. First, an apparatus is utilized to acquire a reading from the body without obtaining a biological sample. Second, an algorithm is utilized to convert this reading into a glucose determination.
- A generalized approach to noninvasive glucose measurement utilizes some form of spectroscopy to acquire the signal or spectrum from a measurement site on the subject's body. Techniques include but are not limited to: impedance, Raman, and fluorescence; as well as techniques using light, from the ultraviolet through the infrared [ultraviolet (200 to 400 nm), visible (400 to 700 nm), near-IR (700 to 2500 nm or 14,286 to 4000 cm−1), infrared (2500 to 14,285 nm or 4000-700 cm−1)]. A specific near infrared range for noninvasive glucose determination in diffuse reflectance mode is about 1100 to 2500 nm or ranges or sets of ranges therein. K. Hazen, Glucose Determination in Biological Matrices Using Near-infrared Spectroscopy, doctoral dissertation, University of Iowa (1995). It is important to note, that these techniques are distinct from the minimally invasive techniques listed above in that the sample analyzed is a portion of the human body in situ, not a biological sample extracted from the human body.
- Potential sites for the noninvasive measurement have been identified from the ear lobe, oral mucosa, arm, and eye to the fingertip. It is important to note that noninvasive techniques do not have to be based upon spectroscopy. Within the context of the invention, any device that reads glucose from the body without penetrating the skin and collecting a biological sample is classified as a noninvasive glucose analyzer.
- To date, noninvasive glucose measurement has conventionally employed a direct measurement approach, in which the net analyte signal due to the absorption of light by glucose in the tissue is used to calculate the glucose concentration. There exist formidable challenges to the development of reliable methods of glucose measurement using a direct approach. Among these challenges are the size of the glucose signal relative to the spectral background, the heterogeneity of the sample, the multi-layered structure of the skin, the rapid variation related to hydration levels, changes in the volume fraction of blood in the tissue, hormonal stimulation, temperature fluctuations, and blood analyte levels. Control of the optical properties of the sample site is essential to the success of any method of noninvasive glucose measurement using a direct measurement approach.
- Calibration And Utilization Of Noninvasive Glucose Meters
- One noninvasive technology, near-infrared spectroscopy, provides the opportunity for both frequent and painless noninvasive measurement of glucose. This approach involves the illumination of a spot on the body with near-infrared (NIR) electromagnetic radiation, light in the wavelength range 700 to 2500 nm. The light is partially absorbed and scattered, according to its interaction with the constituents of the tissue. The actual tissue volume that is sampled is the portion of irradiated tissue from which light is collected and transported to the spectrometer detection system. Generation of a suitable calibration involves development of a mathematical relationship between an in vivo near-infrared spectral measurement and a corresponding reference blood glucose concentration. The model generation process includes the collection of a multiplicity of matched spectrum/reference glucose pairs followed by the calculation of a regression model between the multiple independent variables contained in each spectral vector and the associated single dependent reference glucose value. Reference blood glucose values are typically obtained directly through the use of measurement tools like the HEMOCUE (YSI, Inc., Yellow Springs Ohio) or any other reliable invasive glucose analyzer.
- The Beer-Lambert Law, equation 1 infra, defines a proportionality constant between glucose concentration and spectral light absorbed at a single spectral wavelength in the special case where no interfering spectral signatures are present. In equation 1, A is the scalar absorbance measurement at a given wavelength of light, ε is the molar absorptivity associated with the molecule of interest at the same given wavelength, b is the distance (or pathlength) that the light travels through the sample, and C is the concentration of the molecule of interest (glucose).
A=εbC - A number of interferences do exist for the near-infrared measurement making the correction for these interferences necessary. Correction is achieved by using multiple wavelengths in each spectrum in a multivariate regression model. Such a model is proven means for compensation of spectral interferences, requiring some measure of uniqueness in the spectral signature of the glucose.
=C - In
equation 2, boldface type denotes vector variables. The expression is interpreted as the outer product of the regression vector k and the absorbance spectrum vector A, consisting of the absorbance at a multiplicity of selected wavelengths, is equal to the glucose concentration C of the sample. - Common multivariate approaches that can be used to solve the
equation 2 for the regression vector k can include partial least squares (PLS) and principal component regression (PCR). Nonparametric methods of calibration such as neural networks and multiple adaptive regression splines (MARS) can also be used to model an expression analogous toequation 2 in the case where Beer's law deviations are present and the relation becomes nonlinear. - Because every method of glucose measurement has error, it is beneficial that the primary reference device, which is used to develop and evaluate noninvasive calibrations for blood glucose, be as accurate as possible to minimize the uncertainty in the model. An instrument with a percentage error of five or less is most desirable. An instrument having a percentage error of up to ten would be suitable, though the error of the device being calibrated may increase.
- Instrumentation
- Non invasive
- A number of technologies have been proposed for measuring glucose non-invasively, all of which involve some type of tissue measurement. Spectroscopy-based noninvasive glucose analyzers utilize the measured interaction of the tissue sample with electromagnetic radiation (EMR) or another type of energy input that leads to an emission of EMR to acquire the signal or spectrum. Examples include but are not limited to Nuclear Magnetic Resonance (NMR) spectroscopy, UV, visible near-infrared, mid-infrared, and far-infrared spectroscopy, tissue impedance spectroscopy, Raman spectroscopy, and fluorescence spectroscopy. The near infrared range for noninvasive glucose determination in diffuse reflectance mode is about 1100 to 2500 nm or ranges therein. Hazen (1995), supra. It is important to define noninvasive techniques as being distinct from invasive techniques in that the noninvasive sample is analyzed in-situ, as opposed to invasively extracting a biological sample through the skin for analysis. The actual tissue volume that is sampled is the portion of irradiated tissue from which light is reflected or transmitted to the spectrometer detection system. All of these techniques share the common characteristic that, as secondary calibration methods, they require a calibration, model or other transformation to convert the measured signal to an estimate of the glucose concentration using reference measurements based on a primary method, such as invasive measurements from samples of venous or capillary blood.
- A number of spectrometer configurations exist for collecting noninvasive spectra from regions of the body. Typically a spectrometer has one or more beam paths from a source to a detector. A light source may include a blackbody source, a tungsten-halogen source, one or more LED's, or one or more laser diodes. For multi-wavelength spectrometers a wavelength selection device may be utilized or a series of optical filters may be utilized for wavelength selection. Wavelength selection devices include dispersive elements such as prisms, and gratings of various types. Nondispersive wavelength selective devices include interferometers, successive illumination of the elements of an LED array, and wavelength selective filters. Detectors may be in the form of one or more single element detectors or one or more arrays or bundles of detectors. Detector materials are selected to obtain the desired signal measurement characteristics over the necessary wavelength ranges. Light collection optics such as fiber optics, lenses, and mirrors are commonly utilized in various configurations within a spectrometer to direct light from the source to the detector by way of a sample.
- The interface of the glucose analyzer to the tissue includes a patient interface module for directing light into and collecting light from the tissue measurement site. Optical conduits for directing and collecting light may include a light pipe, fiber optics, a focusing lens system, or a light directing mirror system.
- The scanning of the tissue can be done continuously when pulsation effects do not affect the tissue area being tested, or the scanning can be done intermittently between pulses. The collected signal (near-infrared radiation in this case) is converted to a voltage and sampled through an analog-to-digital converter for analysis on a microprocessor based system and the result displayed.
- Related Skin Physiology
- One of the primary functions of cutaneous skin is to provide a means for thermoregulatory control of body temperature. Blood at approximately 98° F. is pumped to the outer skin layers to provide nutrients, is a means for waste removal, and is a mechanism for thermoregulatory control. In the case of warm ambient temperatures, heat can be dissipated from the core of the body when increased blood flow is combined with the cooling effects of sweat evaporation on the skin surface. In the case of cool ambient temperatures, heat can also be used to warm a cool skin surface, but rapid heat loss associated with touching cold objects is limited by constrictively reducing blood flow to the superficial tissues. These thermoregulatory mechanisms typically use constriction or dilation of capillary vessels and the concomitant variation in blood flow to control the potential for heat transfer to and from the body. Capillary diameters can vary tenfold during these processes.
- A tenfold variation in capillary vessel diameter can lead to substantial changes in the composition and optical properties of the tissue. Such variation in the measured tissue sample can lead to poor sampling precision over a sequential series of measurements. Sample normalization of a varying signal derived from the heterogeneous, layered structure of skin can be of limited effectiveness due to spectral nonlinearities imposed by the compositional variation of the layers and the sequential path of light through the various layers of skin. Specifically, the broadband source light is filtered uniquely in the wavelength domain by each skin layer according to the changing compositions and varying optical densities that result with a perfusion shift in the tissue. The result is that the optical sample is destabilized in a nonlinear manner that is difficult or impossible to normalize with a high degree of accuracy. It follows that the modeling of glucose concentration will be most efficacious under the conditions that variations in the optical properties of the sample are minimized excepting where changes in the optical properties are a direct result of glucose variation.
- Accuracy and robustness are improved with thermal control in the case of either a conventional direct measurement or an indirect measurement, described below, of blood glucose. Thermally or mechanically stimulated changes in optical properties will complicate direct noninvasive glucose determinations. Thermal perturbations are addressed herein using the knowledge of human vascular response to heat and cold and by limiting temperature transients due to skin contact with objects that differ by more than 5 degrees F. from typical resting skin temperatures of 85-95° F.
- There are a number of issues related to obtaining representative samples in analytical technologies. Factors affecting sample stability may be environmental or natural physiological variation that can arise from variations in sample site location or time dependent physiologies. Environmental factors, such as temperature, can affect instrumentation, electronics, and physiological components. For example, in near-IR spectroscopy, environmental temperature may affect either or both of the alignment of a spectrometer and the temperature of the probing device, which secondarily affects the tissue temperature upon contact. In the case of noninvasive glucose determination performed via near-IR spectroscopy, the result of these changes is a change in the acquired spectra due to the effect of temperature and pressure on tissue optical properties.
- Furthermore, temperature effects the localized perfusion of the tissue. The localized perfusion is important for several reasons. First, vasodilatation of the surface capillaries affects the amount of blood present near the skin surface. This change can effect the glucose concentration in the sampled tissue volume. Second, it has been reported that blood at alternative sites, such as the forearm, can contain glucose concentrations that are dampened and/or delayed versus blood in well perfused areas, such as an artery, vein, or fingertip capillary bed. K. Jungheim, T. Koschinsky, Glucose Monitoring at the Arm, Diabetes Care, 25:956-960 (2002); and K. Jungheim, T. Koschinsky, Risky delay of hypoglycemia detection by glucose monitoring at the arm, Diabetes Care, 24:1303-1304 (2001); and J. Fischer, K. Hazen, M. Welch, L. Hockersmith, J. Coates, Comparisons of capillary blood glucose concentrations from the fingertips and the volar aspects of the left and right forearms, American Diabetes Association, 62nd Annual Meeting (Jun. 14, 2002).
- A number of approaches have been utilized to minimize this lag. For example, M. Rohrscheib, C. Gardner, M. Robinson, Method and apparatus for noninvasive blood analyte measurement with fluid compartment equilibration”, U.S. Pat. No. 6,240,306 (May 29, 2001) suggests applying heat to the skin surface to increase perfusion. The Rohrscheib patent describes elevating localized skin temperature from 35° C. by at least 5° C. and preferably by about 7° C. in order to equilibrate the glucose concentration between the vascular system and skin tissue. The reported mechanism involves the local dilation of capillaries to increase blood flow, which results in a partial equalization of the venous and capillary glucose concentrations. Rohrscheib, et al. further teach use of vasodilating agents such as nicotinic acid, methyl nicotinamide, minoxidil, nitroglycerin, histamine, capsaicin, or menthol to increase local blood flow. While tissue perfusion can be increased to maximal levels though application of thermal energy, it has the additional undesirable effect of destabilizing optical properties of the tissue sample.
- A method and apparatus for sample site temperature stabilization in conjunction with near-IR based noninvasive glucose determination has been reported. K. Hazen (1995), supra, pp. 193-249. This method utilizes a heater in thermal contact with the sampling site, but the methodology is for a direct reading of glucose and the temperatures are elevated to above forty degrees centigrade.
- There exists therefore a need in the art for a noninvasive method of glucose measurement that overcomes the difficulties inherent in methods based on direct measurement of a net analyte signal. There further exists a need to maximize the reliability of such a method by providing a means for controlling and/or eliminating the fluctuation of optical properties of tissue sample by stabilizing perfusion of the sample site.
- The invention provides methods and a system for non-invasively measuring key constituents and properties of tissue. A target analyte is measured indirectly based on the natural response of tissue to variations in analyte concentration. The indirect method of measuring utilizes factors that are effected by or correlated with the concentration of glucose, such as the index of refraction, electrolyte distribution or reduced scattering coefficient of the bulk tissue. An indirect measurement means that an ancillary effect due to changes in glucose concentration is being measured.
- The reliability of the measurement is greatly improved by stabilizing the optical properties of the tissue at the measurement site, thus means are provided for regulating blood perfusion rates at the sample site. In one embodiment, perfusion is monitored and stabilized by spectroscopically measuring a control parameter, such as skin temperature, that directly affects perfusion. The control parameter is maintained in a range about a set point, thus stabilizing perfusion. Skin temperature is controlled using a variety of means, including the use of active heating and cooling elements, passive devices, such as thermal wraps, and through the use of a heated coupling medium having favorable heat transfer properties.
-
FIG. 1 provides a flow diagram of a method for regulating a control parameter at a tissue measurement site according to the invention; -
FIG. 2 provides a schematic diagram of a subject interface module according to the invention; and -
FIG. 3 shows a schematic diagram of an apparatus for noninvasive glucose determination according to the invention. - Indirect Measurement
- A method for indirectly determining a concentration of a target analyte, such as glucose, non-invasively is described in the commonly-assigned U.S. patent application Ser. No. 10/xxx,xxx (SENS0006), the entirety of which is hereby incorporated by reference as if fully set forth herein. The method takes advantage of the fact that tissue properties are responsive to and reflect physiological variations in the tissue related to variations in the concentration of analyte. An analytical signal is collected at a sampling site on a subject's body. Features are extracted from the analytical signals that are indicative of the target analyte on the sampled tissue. Analyte concentration is calculated indirectly by applying a calibration model to the features. The extracted features are reflective of changes in tissue properties, which themselves are responsive to and reflect physiological variations in the tissue related to variations in the concentration of analyte. Thus, indirect measurement measures a target analyte by measuring an ancillary effect of the target analyte.
- The invention provides a method and apparatus of noninvasive glucose measurement in which blood perfusion at the sample site is regulated through regulation of a control parameter that directly influences perfusion, such as skin temperature.
FIG. 1 shows a flow diagram of a method for noninvasive glucose determination that includes perfusion control at the sample site. As shown inFIG. 1 , perfusion is controlled through the provision of a feedback loop that maintains the control parameter within an acceptable range about a set point. For example, blood perfusion increases rapidly and is volatile above skin temperatures of 40° C., thus it is desirable to regulate skin temperature at the sampling site to a range between approximately 30 and 40° C.; preferably the skin temperature is controlled between 30 and 35° C. More preferably, the skin is controlled to within one degree of a control set-point in a range of 30 to 35° C. The control set point is established by the environmental conditions and the patient physiology at the time of a periodic instrument bias correction. Notably, only the outermost 100 μm of skin temperature need be controlled, as below this depth the capillary bed controls the skin temperature. While the invention specifically provides a method of indirect measurement as described above, the principle of controlling blood perfusion is also readily applied to noninvasive measurement approaches in which analyte concentration is directly determined based on the net analyte signal. - In the preferred embodiment, local perfusion is monitored spectroscopically and controlled through regulation of the control parameter. The invented method generally includes steps of:
-
- Measuring an
analytical signal 101. As shown inFIG. 1 , the analytical signal is a near-infrared absorbance spectrum. However, the principles of the invention are applicable to other noninvasive measurement technologies as well. Measurement may be performed using instrumentation as shown inFIG. 3 ; - The control parameter is measured spectroscopically through application of a first calibration model to the
spectral measurement 102, and the value of the parameter relative to theset point 103 is determined; - The relative value of the control parameter is evaluated 104 to determine if it is within the acceptable range about the
set point 103; - If the control parameter measurement is acceptable, a
glucose calibration 107 is applied to the spectral measurement to produce a glucose measurement; - If the control parameter measurement isn't within an acceptable, an error is generated, and the value is supplied as an
input 105 to anelement 106 for regulating the control parameter. The loop is repeated, with the control parameter being repeatedly evaluated until the measurement is within the acceptable range.
- Measuring an
- One embodiment of the above invention provides a method and apparatus for minimizing the confounding effects in a noninvasive spectral measurement attributable to shifts in skin temperature at the tissue measurement site. Near-infrared measurements of skin combined with associated skin temperature reference measurements are used to develop NIR temperature calibrations that require only NIR tissue scans to predict skin surface temperature. Methods of developing calibrations for spectral analysis may employ a variety of multivariate analytical techniques that are well known to those skilled in the art. NIR skin temperature calibration is made possible by the known shifting of the 1450 or 1900 nm water band with variations in skin temperature. The calibration model incorporates the shift information implicitly in the multivariate regression coefficients. Temperature measurement and control of human tissue is important in noninvasive NIR measurement because it provides a means of simplifying the complex overlapping spectral effects that inhibit extraction of the analyte signal. The extra temperature measurement hardware and the associated cost and complexity are avoided by using NIR temperature measurement.
- Skin temperature at the measurement site is spectroscopically monitored by calculating temperature values through the application of a multivariate calibration model that correlates spectroscopic changes with shifts in skin temperature. Advantageously, thermal time constants imposed by conventional temperature sensing devices are eliminated, providing near-instantaneous temperature readings.
- Temperature control may be either active or passive.
- Passive control is achieved through the selective application and removal of an occlusive thermal wrap. Active control is provided by a thermistor applied to the skin in the vicinity of the measurement site. Active and passive control may be applied in complementary fashion or they may be used separately. In a particularly preferred embodiment of the invention, the control means is incorporated into the measurement instrument, wherein the calculated skin temperature values provide the feedback in a closed loop that drives the control device. In an alternate embodiment of the invention, the temperature values are supplied to an operator, who then applies active and/or passive control to achieve and maintain a skin temperature within the target range. By monitoring skin temperature spectroscopically and employing methods of passive and/or active control it is possible to reduce the effects of skin temperature variation on the spectral measurement. Active control may be by way of a conductive element, as described above, or it may also be provided by a radiative element.
- Non-Spectroscopic Control
- Alternately, perfusion can be controlled in an open-loop fashion by maintaining skin temperature at a specific set-point, as shown in
FIG. 2 . The control of skin temperature is performed conductively through heating andcooling element 201 included as part of apatient interface module 200. In one embodiment, the heating and cooling element may be energy transfer pads. Alternately, skin temperature is controlled through radiative energy transfer from an energy source. The system may include means for monitoring the skin temperature at the measurement site either spectroscopically or through a temperature probe (not shown). During use, anoninvasive probe 203 is placed against the skin at thesample site 204. Acoupling medium 205 is employed between thepatient interface 202 and thetissue 204. The coupling medium serves to facilitate heat transfer between thepatient interface 202 and thetissue 204. - Skin Temperature Regulation Using Heated Coupling Medium.
- As previously mentioned, the coupling medium itself may serve to control skin temperature at the sampling site. Thus, an embodiment of the invention is possible in which a heated coupling medium provides the thermal energy to maintain the skin of a sampling site at or near a set point. A number of compounds are suitable for use as a coupling medium; for example, silicone oil. Glycerol and mineral oil could also be used, but they are less desirable alternatives, in view of the fact that both materials contain carbon-hydrogen bonds that could interfere with spectroscopic analysis of an analyte such as glucose.
- A particularly preferred embodiment of the coupling medium is the perfluorinated liquid FLUORINERT, either FC-40 or FC-70 (3M COMPANY, ST. PAUL Minn.). While the FLUORINERT functions to reduce surface reflection variations in the noninvasive 20 measurement, its heat transfer properties are well suited for use as a thermal regulator. Because the FLUORINERT comes into contact with skin at the measurement site, heat can be transferred across the skin if the temperature of the FLUORINERT differs from that of the skin.
- Heated FLUORINERT can be used in place of a heated probe with the advantage of reduced power consumption when compared with a temperature controlled metal probe contact surface. The advantage is gained by the rapid heating of small amounts of FLUORINERT just prior to the measurement. Periodic rapid heating saves power over continuous heating of the metal heater contact surface thereby reducing power consumption and lengthening battery life. The use of heated FLUORINERT also allows for the relocation of the heating electronics away from the probe for increased safety. The use of heated FLUORINERT also allows for the heating of the tissue at the measurement site, which is not heated directly by the probe surface heater as it is not in contact with the tissue at the measurement site. During use, a portion of the heated FLUROINERT is disposed between the patient interface of the probe and the skin surface of the measurement site. Alternatively, the coupling fluid may be heated by the source element in embodiments where the source element is in close proximity to the sampling site.
- Instrumentation
- While a variety of sensors or instrument configurations are suitable for practice of the invention,
FIG. 3 provides a schematic diagram of a preferred embodiment of the sensor. The sensor includes a radiation source such as a tungsten halogen near-infrared radiation source 301, awavelength selection filter 302 passing light in a range of approximately 1150 to 1850 nm;optional illumination fibers 303 for conveying the source photons to an in-vivo skin sample 204; aninterface 200 to the sample site, for example, a patient's forearm;detection fibers 306 for gathering diffusely reflected and transflected radiation from the skin to aspectrum analyzer 307 that includes, for example a grating (not shown), and a detector array (not shown) to detect the radiation; an AD (analog-to-digital)converter 308 for converting the detected signal to a voltage; and processing means 309 for converting the voltage into a glucose concentration. - Although the invention has been described herein with reference to certain preferred embodiments, one skilled in the art will readily appreciate that other applications may be substituted for those set forth herein without departing from the spirit and scope of the present invention. Accordingly, the invention should only be limited by the claims included below.
Claims (24)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/954,856 US6839584B2 (en) | 2000-05-02 | 2001-09-17 | Method and apparatus for minimizing spectral interference due to within and between sample variations during in-situ spectral sampling of tissue |
PCT/US2001/029232 WO2002026124A1 (en) | 2000-09-26 | 2001-09-18 | Method and apparatus for minimizing spectral interference during in-situ spectral tissue sampling |
AU2001292774A AU2001292774A1 (en) | 2000-09-26 | 2001-09-18 | Method and apparatus for minimizing spectral interference during in-situ spectral tissue sampling |
US10/384,049 US7509153B2 (en) | 2000-09-26 | 2003-03-07 | Method and apparatus for control of skin perfusion for indirect glucose measurement |
PCT/US2004/006786 WO2004080281A2 (en) | 2000-09-26 | 2004-03-05 | Method and apparatus for control of skin perfusion for indirect glucose measurement |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23536900P | 2000-09-26 | 2000-09-26 | |
US09/955,531 US6640117B2 (en) | 2000-09-26 | 2001-09-17 | Method and apparatus for minimizing spectral effects attributable to tissue state variations during NIR-based non-invasive blood analyte determination |
US36334502P | 2002-03-08 | 2002-03-08 | |
US10/349,573 US7039446B2 (en) | 2001-01-26 | 2003-01-22 | Indirect measurement of tissue analytes through tissue properties |
US10/384,049 US7509153B2 (en) | 2000-09-26 | 2003-03-07 | Method and apparatus for control of skin perfusion for indirect glucose measurement |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/955,531 Continuation-In-Part US6640117B2 (en) | 2000-09-26 | 2001-09-17 | Method and apparatus for minimizing spectral effects attributable to tissue state variations during NIR-based non-invasive blood analyte determination |
US10/349,573 Continuation-In-Part US7039446B2 (en) | 1997-08-14 | 2003-01-22 | Indirect measurement of tissue analytes through tissue properties |
Publications (3)
Publication Number | Publication Date |
---|---|
US20040039271A1 US20040039271A1 (en) | 2004-02-26 |
US20080200783A9 true US20080200783A9 (en) | 2008-08-21 |
US7509153B2 US7509153B2 (en) | 2009-03-24 |
Family
ID=31892028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/384,049 Expired - Fee Related US7509153B2 (en) | 2000-05-02 | 2003-03-07 | Method and apparatus for control of skin perfusion for indirect glucose measurement |
Country Status (1)
Country | Link |
---|---|
US (1) | US7509153B2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10736518B2 (en) | 2015-08-31 | 2020-08-11 | Masimo Corporation | Systems and methods to monitor repositioning of a patient |
USD897098S1 (en) | 2018-10-12 | 2020-09-29 | Masimo Corporation | Card holder set |
US10835130B2 (en) | 2014-12-19 | 2020-11-17 | Samsung Electronics Co., Ltd. | Noninvasive blood glucose measurement method and apparatus |
US10959652B2 (en) | 2001-07-02 | 2021-03-30 | Masimo Corporation | Low power pulse oximeter |
US10984911B2 (en) | 2005-03-01 | 2021-04-20 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US11076777B2 (en) | 2016-10-13 | 2021-08-03 | Masimo Corporation | Systems and methods for monitoring orientation to reduce pressure ulcer formation |
US11439329B2 (en) | 2011-07-13 | 2022-09-13 | Masimo Corporation | Multiple measurement mode in a physiological sensor |
US11602289B2 (en) | 2015-02-06 | 2023-03-14 | Masimo Corporation | Soft boot pulse oximetry sensor |
US11717210B2 (en) | 2010-09-28 | 2023-08-08 | Masimo Corporation | Depth of consciousness monitor including oximeter |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8581697B2 (en) * | 2001-04-11 | 2013-11-12 | Trutouch Technologies Inc. | Apparatuses for noninvasive determination of in vivo alcohol concentration using raman spectroscopy |
US8174394B2 (en) * | 2001-04-11 | 2012-05-08 | Trutouch Technologies, Inc. | System for noninvasive determination of analytes in tissue |
US7299082B2 (en) * | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
US8730047B2 (en) | 2004-05-24 | 2014-05-20 | Trutouch Technologies, Inc. | System for noninvasive determination of analytes in tissue |
US20080319286A1 (en) * | 2004-05-24 | 2008-12-25 | Trent Ridder | Optical Probes for Non-Invasive Analyte Measurements |
US20110178420A1 (en) * | 2010-01-18 | 2011-07-21 | Trent Ridder | Methods and apparatuses for improving breath alcohol testing |
US8515506B2 (en) * | 2004-05-24 | 2013-08-20 | Trutouch Technologies, Inc. | Methods for noninvasive determination of in vivo alcohol concentration using Raman spectroscopy |
GB0603006D0 (en) * | 2006-02-15 | 2006-03-29 | Dialog Devices Ltd | Assessing blood supply to a peripheral portion of an animal |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
US7973925B2 (en) * | 2007-02-06 | 2011-07-05 | C8 Medisensors Inc. | Apparatus for stabilizing mechanical, thermal, and optical properties and for reducing the fluorescence of biological samples for optical evaluation |
US10542919B2 (en) * | 2008-03-25 | 2020-01-28 | St. Louis Medical Devices, Inc. | Method and system for non-invasive blood glucose detection utilizing spectral data of one or more components other than glucose |
JP5676432B2 (en) | 2008-05-22 | 2015-02-25 | ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Of The University Of Missouri | Method and system for non-invasive and optical detection of blood glucose using spectral data analysis |
US8577431B2 (en) | 2008-07-03 | 2013-11-05 | Cercacor Laboratories, Inc. | Noise shielding for a noninvasive device |
US8630691B2 (en) | 2008-08-04 | 2014-01-14 | Cercacor Laboratories, Inc. | Multi-stream sensor front ends for noninvasive measurement of blood constituents |
WO2010141262A1 (en) * | 2009-06-04 | 2010-12-09 | C8 Medisensors Inc. | Apparatus for increasing blood perfusion and improving heat sinking to skin |
US8688183B2 (en) | 2009-09-03 | 2014-04-01 | Ceracor Laboratories, Inc. | Emitter driver for noninvasive patient monitor |
WO2011040599A1 (en) | 2009-10-02 | 2011-04-07 | シャープ株式会社 | Device for monitoring blood vessel conditions and method for monitoring same |
US9173604B2 (en) | 2010-03-19 | 2015-11-03 | Sharp Kabushiki Kaisha | Measurement device, measurement method, measurement result processing device, measurement system, measurement result processing method, control program, and recording medium |
US20120226117A1 (en) | 2010-12-01 | 2012-09-06 | Lamego Marcelo M | Handheld processing device including medical applications for minimally and non invasive glucose measurements |
US8411265B2 (en) | 2011-06-14 | 2013-04-02 | C8 Medisensors Inc. | Apparatus for stabilizing mechanical, thermal, and optical properties and for reducing the fluorescence of biological samples for optical evaluation |
US20130338512A1 (en) | 2012-03-12 | 2013-12-19 | Ivwatch, Llc | System and Method for Mitigating the Effects of Tissue Blood Volume Changes to Aid in Diagnosing Infiltration or Extravasation in Animalia Tissue |
US9351672B2 (en) | 2012-07-16 | 2016-05-31 | Timothy Ruchti | Multiplexed pathlength resolved noninvasive analyzer apparatus with stacked filters and method of use thereof |
US9585604B2 (en) | 2012-07-16 | 2017-03-07 | Zyomed Corp. | Multiplexed pathlength resolved noninvasive analyzer apparatus with dynamic optical paths and method of use thereof |
US20150018646A1 (en) | 2013-07-12 | 2015-01-15 | Sandeep Gulati | Dynamic sample mapping noninvasive analyzer apparatus and method of use thereof |
US9351671B2 (en) | 2012-07-16 | 2016-05-31 | Timothy Ruchti | Multiplexed pathlength resolved noninvasive analyzer apparatus and method of use thereof |
US10827961B1 (en) | 2012-08-29 | 2020-11-10 | Masimo Corporation | Physiological measurement calibration |
US9636060B2 (en) | 2012-12-18 | 2017-05-02 | Abbott Diabetes Care Inc. | Dermal layer analyte sensing devices and methods |
US9668686B2 (en) | 2013-03-15 | 2017-06-06 | Abbott Diabetes Care Inc. | In vivo glucose sensing in an increased perfusion dermal layer |
WO2015051288A1 (en) * | 2013-10-03 | 2015-04-09 | Leszinske Alan J | Apparatus and method for automated blood analyte monitoring |
AU2014374361B9 (en) | 2013-12-31 | 2019-07-04 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
WO2016054079A1 (en) | 2014-09-29 | 2016-04-07 | Zyomed Corp. | Systems and methods for blood glucose and other analyte detection and measurement using collision computing |
US10874333B2 (en) | 2015-09-15 | 2020-12-29 | Massachusetts Institute Of Technology | Systems and methods for diagnosis of middle ear conditions and detection of analytes in the tympanic membrane |
US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
KR102655736B1 (en) * | 2016-07-19 | 2024-04-05 | 삼성전자주식회사 | Heterogeneous spectrum-based blood sugar estimation apparatus and method |
JP2021530341A (en) | 2018-07-16 | 2021-11-11 | ビービーアイ、メディカル、イノベーションズ、リミテッド、ライアビリティー、カンパニーBbi Medical Innovations, Llc | Measurement of perfusion and oxygenation |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5007423A (en) * | 1989-10-04 | 1991-04-16 | Nippon Colin Company Ltd. | Oximeter sensor temperature control |
US5153368A (en) * | 1991-05-28 | 1992-10-06 | Ici Americas, Inc. | Filtered electrical connection assembly using potted ferrite element |
US5402777A (en) * | 1991-06-28 | 1995-04-04 | Alza Corporation | Methods and devices for facilitated non-invasive oxygen monitoring |
US5487384A (en) * | 1993-02-25 | 1996-01-30 | Blue Marble Research, Inc. | Kinematic assay of plasma glucose concentration without blood sampling |
US5551422A (en) * | 1992-11-09 | 1996-09-03 | Boehringer Mannheim Gmbh | Method and apparatus for analytical determination of glucose in a biological matrix |
US5615672A (en) * | 1993-01-28 | 1997-04-01 | Optiscan, Inc. | Self-emission noninvasive infrared spectrophotometer with body temperature compensation |
US5876121A (en) * | 1994-08-05 | 1999-03-02 | Mcgill University | Substrate temperature measurement by infrared spectroscopy |
US6002597A (en) * | 1999-02-08 | 1999-12-14 | Lucent Technologies Inc. | Synchronous rectifier having dynamically adjustable current rating and method of operation thereof |
US6002953A (en) * | 1998-05-06 | 1999-12-14 | Optix Lp | Non-invasive IR transmission measurement of analyte in the tympanic membrane |
US6025597A (en) * | 1995-10-17 | 2000-02-15 | Optiscan Biomedical Corporation | Non-invasive infrared absorption spectrometer for measuring glucose or other constituents in a human or other body |
US6044285A (en) * | 1997-11-12 | 2000-03-28 | Lightouch Medical, Inc. | Method for non-invasive measurement of an analyte |
US6049727A (en) * | 1996-07-08 | 2000-04-11 | Animas Corporation | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
US6049728A (en) * | 1997-11-25 | 2000-04-11 | Trw Inc. | Method and apparatus for noninvasive measurement of blood glucose by photoacoustics |
US6072180A (en) * | 1995-10-17 | 2000-06-06 | Optiscan Biomedical Corporation | Non-invasive infrared absorption spectrometer for the generation and capture of thermal gradient spectra from living tissue |
US6119026A (en) * | 1997-12-04 | 2000-09-12 | Hewlett-Packard Company | Radiation apparatus and method for analysis of analytes in sample |
US6125297A (en) * | 1998-02-06 | 2000-09-26 | The United States Of America As Represented By The United States National Aeronautics And Space Administration | Body fluids monitor |
US6152876A (en) * | 1997-04-18 | 2000-11-28 | Rio Grande Medical Technologies, Inc. | Method for non-invasive blood analyte measurement with improved optical interface |
US6161028A (en) * | 1999-03-10 | 2000-12-12 | Optiscan Biomedical Corporation | Method for determining analyte concentration using periodic temperature modulation and phase detection |
US6216022B1 (en) * | 2000-06-22 | 2001-04-10 | Biosafe Laboratories, Inc. | Implantable optical measurement device and method for using same |
US6240306B1 (en) * | 1995-08-09 | 2001-05-29 | Rio Grande Medical Technologies, Inc. | Method and apparatus for non-invasive blood analyte measurement with fluid compartment equilibration |
US6241663B1 (en) * | 1998-05-18 | 2001-06-05 | Abbott Laboratories | Method for improving non-invasive determination of the concentration of analytes in a biological sample |
US6280381B1 (en) * | 1999-07-22 | 2001-08-28 | Instrumentation Metrics, Inc. | Intelligent system for noninvasive blood analyte prediction |
US6309884B1 (en) * | 1997-02-26 | 2001-10-30 | Diasense, Inc. | Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose |
US6466808B1 (en) * | 1999-11-22 | 2002-10-15 | Mallinckrodt Inc. | Single device for both heating and temperature measurement in an oximeter sensor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6662030B2 (en) | 1998-05-18 | 2003-12-09 | Abbott Laboratories | Non-invasive sensor having controllable temperature feature |
CA2387789A1 (en) | 1999-10-15 | 2001-04-26 | Abbott Laboratories | Method for modulating light penetration depth in tissue and diagnostic applications using same |
-
2003
- 2003-03-07 US US10/384,049 patent/US7509153B2/en not_active Expired - Fee Related
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5007423A (en) * | 1989-10-04 | 1991-04-16 | Nippon Colin Company Ltd. | Oximeter sensor temperature control |
US5153368A (en) * | 1991-05-28 | 1992-10-06 | Ici Americas, Inc. | Filtered electrical connection assembly using potted ferrite element |
US5402777A (en) * | 1991-06-28 | 1995-04-04 | Alza Corporation | Methods and devices for facilitated non-invasive oxygen monitoring |
US5551422A (en) * | 1992-11-09 | 1996-09-03 | Boehringer Mannheim Gmbh | Method and apparatus for analytical determination of glucose in a biological matrix |
US5615672A (en) * | 1993-01-28 | 1997-04-01 | Optiscan, Inc. | Self-emission noninvasive infrared spectrophotometer with body temperature compensation |
US5487384A (en) * | 1993-02-25 | 1996-01-30 | Blue Marble Research, Inc. | Kinematic assay of plasma glucose concentration without blood sampling |
US5876121A (en) * | 1994-08-05 | 1999-03-02 | Mcgill University | Substrate temperature measurement by infrared spectroscopy |
US6240306B1 (en) * | 1995-08-09 | 2001-05-29 | Rio Grande Medical Technologies, Inc. | Method and apparatus for non-invasive blood analyte measurement with fluid compartment equilibration |
US6025597A (en) * | 1995-10-17 | 2000-02-15 | Optiscan Biomedical Corporation | Non-invasive infrared absorption spectrometer for measuring glucose or other constituents in a human or other body |
US6072180A (en) * | 1995-10-17 | 2000-06-06 | Optiscan Biomedical Corporation | Non-invasive infrared absorption spectrometer for the generation and capture of thermal gradient spectra from living tissue |
US6049727A (en) * | 1996-07-08 | 2000-04-11 | Animas Corporation | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
US6309884B1 (en) * | 1997-02-26 | 2001-10-30 | Diasense, Inc. | Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose |
US6152876A (en) * | 1997-04-18 | 2000-11-28 | Rio Grande Medical Technologies, Inc. | Method for non-invasive blood analyte measurement with improved optical interface |
US6377828B1 (en) * | 1997-11-12 | 2002-04-23 | Lightouch Medical, Inc. | Method for non-invasive measurement of an analyte |
US6044285A (en) * | 1997-11-12 | 2000-03-28 | Lightouch Medical, Inc. | Method for non-invasive measurement of an analyte |
US6049728A (en) * | 1997-11-25 | 2000-04-11 | Trw Inc. | Method and apparatus for noninvasive measurement of blood glucose by photoacoustics |
US6119026A (en) * | 1997-12-04 | 2000-09-12 | Hewlett-Packard Company | Radiation apparatus and method for analysis of analytes in sample |
US6125297A (en) * | 1998-02-06 | 2000-09-26 | The United States Of America As Represented By The United States National Aeronautics And Space Administration | Body fluids monitor |
US6002953A (en) * | 1998-05-06 | 1999-12-14 | Optix Lp | Non-invasive IR transmission measurement of analyte in the tympanic membrane |
US6241663B1 (en) * | 1998-05-18 | 2001-06-05 | Abbott Laboratories | Method for improving non-invasive determination of the concentration of analytes in a biological sample |
US6002597A (en) * | 1999-02-08 | 1999-12-14 | Lucent Technologies Inc. | Synchronous rectifier having dynamically adjustable current rating and method of operation thereof |
US6161028A (en) * | 1999-03-10 | 2000-12-12 | Optiscan Biomedical Corporation | Method for determining analyte concentration using periodic temperature modulation and phase detection |
US6280381B1 (en) * | 1999-07-22 | 2001-08-28 | Instrumentation Metrics, Inc. | Intelligent system for noninvasive blood analyte prediction |
US6466808B1 (en) * | 1999-11-22 | 2002-10-15 | Mallinckrodt Inc. | Single device for both heating and temperature measurement in an oximeter sensor |
US6216022B1 (en) * | 2000-06-22 | 2001-04-10 | Biosafe Laboratories, Inc. | Implantable optical measurement device and method for using same |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11219391B2 (en) | 2001-07-02 | 2022-01-11 | Masimo Corporation | Low power pulse oximeter |
US10959652B2 (en) | 2001-07-02 | 2021-03-30 | Masimo Corporation | Low power pulse oximeter |
US10980455B2 (en) | 2001-07-02 | 2021-04-20 | Masimo Corporation | Low power pulse oximeter |
US11545263B2 (en) | 2005-03-01 | 2023-01-03 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US10984911B2 (en) | 2005-03-01 | 2021-04-20 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US11430572B2 (en) | 2005-03-01 | 2022-08-30 | Cercacor Laboratories, Inc. | Multiple wavelength sensor emitters |
US11717210B2 (en) | 2010-09-28 | 2023-08-08 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US11439329B2 (en) | 2011-07-13 | 2022-09-13 | Masimo Corporation | Multiple measurement mode in a physiological sensor |
US10835130B2 (en) | 2014-12-19 | 2020-11-17 | Samsung Electronics Co., Ltd. | Noninvasive blood glucose measurement method and apparatus |
US11602289B2 (en) | 2015-02-06 | 2023-03-14 | Masimo Corporation | Soft boot pulse oximetry sensor |
US10736518B2 (en) | 2015-08-31 | 2020-08-11 | Masimo Corporation | Systems and methods to monitor repositioning of a patient |
US11076777B2 (en) | 2016-10-13 | 2021-08-03 | Masimo Corporation | Systems and methods for monitoring orientation to reduce pressure ulcer formation |
USD989327S1 (en) | 2018-10-12 | 2023-06-13 | Masimo Corporation | Holder |
USD897098S1 (en) | 2018-10-12 | 2020-09-29 | Masimo Corporation | Card holder set |
Also Published As
Publication number | Publication date |
---|---|
US7509153B2 (en) | 2009-03-24 |
US20040039271A1 (en) | 2004-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7509153B2 (en) | Method and apparatus for control of skin perfusion for indirect glucose measurement | |
JP4189322B2 (en) | Compact instrument for non-invasive measurement of glucose by near infrared spectroscopy | |
KR100893432B1 (en) | A method for noninvasive measurement of a target analyte property in a tissue sample and an apparatus therefor | |
CA2373860C (en) | Method and apparatus for non-invasive blood analyte measurement | |
US6640117B2 (en) | Method and apparatus for minimizing spectral effects attributable to tissue state variations during NIR-based non-invasive blood analyte determination | |
US7016713B2 (en) | Non-invasive determination of direction and rate of change of an analyte | |
US6998247B2 (en) | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers | |
WO2006079797A2 (en) | Apparatus for measurement of analyte concentration | |
JP2007516014A (en) | Light stimulation method and apparatus combined with glucose determination | |
WO2004080281A2 (en) | Method and apparatus for control of skin perfusion for indirect glucose measurement | |
WO1997036540A1 (en) | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator | |
Yeh et al. | Differences in thermal optical response between intact diabetic and nondiabetic human skin | |
Yeh et al. | Longitudinal 3-week tracking of blood glucose concentration from thermo-optical response measurements on human skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SENSYS MEDICAL, INC., ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLANK, THOMAS B.;RUCHTI, TIMOTHY L.;MATTU, MUTUA;AND OTHERS;REEL/FRAME:014249/0966 Effective date: 20030325 |
|
AS | Assignment |
Owner name: GLENN PATENT GROUP, CALIFORNIA Free format text: LIEN;ASSIGNOR:SENSYS MEDICAL, INC.;REEL/FRAME:022117/0887 Effective date: 20090120 Owner name: GLENN PATENT GROUP,CALIFORNIA Free format text: LIEN;ASSIGNOR:SENSYS MEDICAL, INC.;REEL/FRAME:022117/0887 Effective date: 20090120 |
|
AS | Assignment |
Owner name: SENSYS MEDICAL, INC., ARIZONA Free format text: LIEN RELEASE;ASSIGNOR:GLENN PATENT GROUP;REEL/FRAME:022542/0360 Effective date: 20090414 Owner name: SENSYS MEDICAL, INC.,ARIZONA Free format text: LIEN RELEASE;ASSIGNOR:GLENN PATENT GROUP;REEL/FRAME:022542/0360 Effective date: 20090414 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: SENSYS MEDICAL, LTD, MALTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SENSYS MEDICAL, INC.;REEL/FRAME:028714/0623 Effective date: 20120428 |
|
AS | Assignment |
Owner name: GLT ACQUISITION CORP., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SENSYS MEDICAL, LIMITED;REEL/FRAME:028912/0036 Effective date: 20120829 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20170324 |